Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsallcareadvantage topical JAK inhibitors Prior Auth…
    Ask Trek AI about this page
    CurrentallcareadvantagePolicy 135.1

    Topical Janus Kinase Inhibitors

    Customize your policy alerts

    Sign up for allcareadvantage Policy 135.1 alerts

    Get alerted when Policy 135.1 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization and coverage criteria for topical JAK inhibitor therapies (delgocitinib, ruxolitinib) for treatment of chronic hand eczema in adult AllCare Advantage members.

    Policy Summary
    Payerallcareadvantage
    PolicyTopical Janus Kinase Inhibitors
    Policy CodePolicy 135.1
    Change TypeNo material changes
    Effective DateSep 25, 2025
    Last ReviewSep 25, 2025
    Next Review DateSep 25, 2027
    Key ActionObtain prior authorization with documentation of FDA‑approved diagnosis, dermatologist involvement, and trials/failures or contraindications to emollients and other recommended therapies.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥18Minimum member age for coverage
    Up to 6 moInitial approval length
    Up to 12 moRenewal approval length
    FDA indicationCoverage limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Max FDA dose
    Quantity limit

    Coverage Criteria for Topical JAK Inhibitors

    Initial and Renewal Therapy

    Covered when ALL of the following are met:

    Initial Approval Criteria: Request is not a renewal; member is ≥18 years old; submitted documentation supports a diagnosis consistent with the FDA‑approved indication (moderate to severe chronic hand eczema); medication is prescribed by or in consultation with a dermatologist; documentation supports failure of or contraindication to an adequate trial of emollient therapy; documentation supports failure of or contraindication to other recommended/formulary therapies (eg, high‑potency topical corticosteroids, topical tacrolimus, phototherapy, oral immunosuppressants).all

    If all met, approve up to 6 months; quantity limited to up to maximum FDA daily dose.

    Renewal Criteria: Request is a renewal of previously approved prior authorization; member met initial approval criteria; chart documentation demonstrates clinical efficacy (eg, reduction in severity or improvement in activities of daily living compared to baseline).all

    If met, approve up to 12 months.

    Coverage for topical Janus kinase (JAK) inhibitors is limited to adults and to the FDA‑approved indication: topical treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. This policy applies to the specified agents (Anzupgo [delgocitinib] and Opzelura [ruxolitinib]) and requires documentation that the request matches the approved indication.

    Use of topical JAK inhibitors is considered not medically necessary when the documented criteria are not met. Examples include: member age <18 years; diagnosis that does not match the FDA‑approved indication of moderate to severe chronic hand eczema; medication not prescribed by or in consultation with a dermatologist; or inadequate documentation of prior trials/failures or contraindications to emollients and other required therapies. Requests lacking required renewal documentation of clinical benefit (eg, improvement in severity or activities of daily living compared to baseline) will also be denied.

    Initial Therapy Requirements

    Initial Therapy

    Initial authorization decision logic

    Initial: Request is not a renewal; member is ≥18 years old; submitted documentation supports diagnosis consistent with the FDA‑approved indication; medication is prescribed by or in consultation with a dermatologist; documentation supports failure of or contraindication to an adequate trial of emollient therapy; documentation supports failure of or contraindication to other recommended/formulary therapies or formulary alternatives.all

    If met, approve up to 6 months; quantity limited to up to maximum FDA daily dose.

    StepRequired prior therapies (trial and fail or contraindication)Coverage action
    1
    Emollient therapy (adequate trial) — documentation of failure or contraindication required
    Must meet requirement — approval contingent on documented failure or contraindication

    Renewal / Continuation Requirements

    Renewal

    Renewal requirements for continuation of topical JAK inhibitor therapy.

    Continuation: Request is for renewal of previously approved therapy; member met the initial approval criteria; documentation in chart notes demonstrates clinical efficacy (eg. reduction in severity or improvement in activities of daily living compared to baseline).all

    If met, approve up to 12 months.

    Prior Authorization and Documentation Requirements

    Prior Authorization

    Prior authorization required and review follows stepwise criteria

    Prior authorization is required for topical JAK inhibitors; review follows the stepwise criteria in the policy including patient age (must be ≥18), documentation of a diagnosis consistent with the FDA‑approved indication (moderate to severe chronic hand eczema), that the medication is prescribed by or in consultation with a dermatologist, and demonstration of required prior therapy trials/failures or contraindications. If all initial criteria are met the policy allows approval up to 6 months (renewal up to 12 months).

    • Initial approval: up to 6 months; Renewal: up to 12 months
    • Quantity limited to up to maximum FDA daily dose
    Step Therapy

    Documented failure or contraindication to emollients and other therapies required

    Approval requires documented failure of, or contraindication to, an adequate trial of emollient therapy and documented failure of or contraindication to other recommended/formulary therapies (for example high‑potency/super‑high‑potency topical corticosteroids, topical tacrolimus, phototherapy, or oral immunosuppressants) before topical JAK inhibitors will be approved.

    Quantity and Dosing Limits

    Topical JAK inhibitors (per agent labeling) — up to maximum FDA daily dose
    Quantity limitTopical JAK inhibitors — up to maximum FDA daily dose (per agent labeling)
    Measurement periodPer day
    Applies toAll topical JAK inhibitor agents included in policy (eg, delgocitinib, ruxolitinib)
    Reference in policyQuantity Limits: Up to max daily dose per FDA

    Definitions and Background

    FDA-approved indication — topical treatment of moderate to severe chronic hand eczema in adults with inadequate response to topical corticosteroids
    FDA-approved indicationTopical treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable.
    Age restrictionAdults only (≥18 years)
    Required prior therapy contextUse intended for patients with inadequate response to topical corticosteroids or when topical corticosteroids are not advisable.
    Example agents coveredAnzupgo (delgocitinib), Opzelura (ruxolitinib)

    Chronic hand eczema (CHE) is managed first‑line with liberal use of emollients and, for active flares, high‑ or super high‑potency topical corticosteroids (groups 1–3). Topical tacrolimus may be used as a steroid‑sparing option or when contact allergy to topical corticosteroids is present. For severe or recalcitrant disease, options include short courses of oral corticosteroids, phototherapy, oral immunosuppressants (eg, methotrexate, cyclosporin, azathioprine), or biologics (eg, dupilumab for atopic CHE). Topical JAK inhibitors (delgocitinib, ruxolitinib) are considered for patients who have failed or cannot use topical corticosteroids and other recommended therapies, and their use should be reserved for patients with prior treatment failure or contraindications to those alternatives.

    Policy Summary
    Payerallcareadvantage
    PolicyTopical Janus Kinase Inhibitors
    Policy CodePolicy 135.1
    Change TypeNo material changes
    Effective DateSep 25, 2025
    Last ReviewSep 25, 2025
    Next Review DateSep 25, 2027
    Key ActionObtain prior authorization with documentation of FDA‑approved diagnosis, dermatologist involvement, and trials/failures or contraindications to emollients and other recommended therapies.
    SourceLink
    On This Page
    Coverage Criteria for Topical JAK InhibitorsInitial Therapy RequirementsRenewal / Continuation RequirementsPrior Authorization and Documentation RequirementsQuantity and Dosing LimitsDefinitions and Background
    • Must document failure or contraindication to emollients (Criteria #6)
    • Must document failure or contraindication to other recommended/formulary therapies (Criteria #7)
    Documentation Required

    Submit supporting clinical documentation and renewal evidence

    Provider must submit chart documentation that supports an FDA‑approved diagnosis (moderate to severe chronic hand eczema), prior trials and failures or contraindications to emollient therapy and other recommended/formulary therapies, and for renewals evidence of clinical efficacy (for example reduction in severity or improved activities of daily living compared to baseline).

    • Documentation supporting diagnosis consistent with FDA‑approved indication (Criteria #3)
    • Documentation of trials/failures or contraindications to emollients (Criteria #6) and other therapies (Criteria #7)
    • For renewals, chart notes demonstrating clinical efficacy (eg, reduction in severity or improvement in ADLs)
    Denial Risk

    Denial risks: age, indication, prescriber specialty, and insufficient documentation

    Denial will be issued if the member is under 18, the submitted diagnosis does not match the FDA‑approved indication, the medication is not prescribed by or in consultation with a dermatologist, or required documentation of prior therapy failure/contraindication or renewal clinical benefit is insufficient.

    • Member age <18 (Criteria #2) — does not meet criteria
    • Diagnosis not consistent with FDA‑approved indication (Criteria #3) — deny
    • Medication not prescribed by or in consultation with a dermatologist (Criteria #4) — deny
    • Insufficient documentation of failure/contraindication to emollients or other required therapies (Criteria #6/#7) — deny
    • For renewals, lack of documentation demonstrating clinical efficacy — deny